Initial SARS-CoV-2 vaccinations prime immune cells to respond to subsequent variants Image: iStock/Thicha Satapitanon Initial SARS-CoV-2 vaccinations prime immune cells to respond to subsequent variants Immunological imprinting from the original ancestral SARS-CoV-2 strain has a significant impact on the antibody responses to the variants and boosters based on them.
Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty is an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center. (Image: Courtesy of Penn Medicine News) Mapping pancreatic cancer to improve immunotherapy Gregory L. Beatty, an associate professor of hematology-oncology and member of Penn Medicine’s Abramson Cancer Center, and his team focus on improving immunotherapy for pancreatic cancer.
‘Dual target’ cell therapy appears to shrink brain tumors Image: iStock/Ildar Imashev ‘Dual target’ cell therapy appears to shrink brain tumors Early Penn Medicine trial results show that targeting two tumor-associated proteins in patients with recurrent glioblastoma may be a promising step toward developing cell therapies for solid tumors.
The mRNA miracle workers CBS News The mRNA miracle workers Nobel laureates Katalin Karikó and Drew Weissman of the Perelman School of Medicine appear on “Sunday Morning” to discuss their careers, their mRNA research, and the COVID-19 vaccines. What makes a breakthrough? ‘Eight steps back’ before making it to the finish line (From left to right) Breakthrough Prize recipients Drew Weissman, Virginia M-Y Lee, Katalin Karikó, and Carl June at a reception on Feb. 13. (Image: Courtesy of Penn Medicine News) What makes a breakthrough? ‘Eight steps back’ before making it to the finish line Four of Penn’s Breakthrough Prize recipients, Carl June, Katalin Karikó, Virginia M-Y Lee, and Drew Weissman, were honored at a reception on Feb. 13. Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more. Blood tests can help diagnose Alzheimer’s—if they’re accurate enough. Not all are NPR Blood tests can help diagnose Alzheimer’s—if they’re accurate enough. Not all are Virginia Man-Yee Lee of the Perelman School of Medicine says it’s likely in the future that anyone older than 60 will get an Alzheimer’s test. How Penn Medicine is changing the world with mRNA nocred How Penn Medicine is changing the world with mRNA Vaccines are just the beginning of the potential for messenger RNA, the Nobel Prize-winning technology. AI detects cancers and immunotherapy biomarker Psychology Today AI detects cancers and immunotherapy biomarker Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy. First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses Image: iStock/Love Employee First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses The therapy tested in a Phase 1 clinical trial might drastically change the way the T cells work, potentially allowing the new CAR T cell product to work where other products have failed. Load More
What makes a breakthrough? ‘Eight steps back’ before making it to the finish line (From left to right) Breakthrough Prize recipients Drew Weissman, Virginia M-Y Lee, Katalin Karikó, and Carl June at a reception on Feb. 13. (Image: Courtesy of Penn Medicine News) What makes a breakthrough? ‘Eight steps back’ before making it to the finish line Four of Penn’s Breakthrough Prize recipients, Carl June, Katalin Karikó, Virginia M-Y Lee, and Drew Weissman, were honored at a reception on Feb. 13.
Secondary cancers following CAR T cell therapy are rare Image: iStock/vitanovski Secondary cancers following CAR T cell therapy are rare A new Penn Medicine analysis shows that the development of any type of second cancer is a rare occurrence, and some of the earliest patients have gone on to experience long-lasting remissions of a decade or more.
Blood tests can help diagnose Alzheimer’s—if they’re accurate enough. Not all are NPR Blood tests can help diagnose Alzheimer’s—if they’re accurate enough. Not all are Virginia Man-Yee Lee of the Perelman School of Medicine says it’s likely in the future that anyone older than 60 will get an Alzheimer’s test. How Penn Medicine is changing the world with mRNA nocred How Penn Medicine is changing the world with mRNA Vaccines are just the beginning of the potential for messenger RNA, the Nobel Prize-winning technology. AI detects cancers and immunotherapy biomarker Psychology Today AI detects cancers and immunotherapy biomarker Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy. First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses Image: iStock/Love Employee First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses The therapy tested in a Phase 1 clinical trial might drastically change the way the T cells work, potentially allowing the new CAR T cell product to work where other products have failed. Load More
How Penn Medicine is changing the world with mRNA nocred How Penn Medicine is changing the world with mRNA Vaccines are just the beginning of the potential for messenger RNA, the Nobel Prize-winning technology.
AI detects cancers and immunotherapy biomarker Psychology Today AI detects cancers and immunotherapy biomarker Daiwei Zhang and Mingyao Li of the Perelman School of Medicine and colleagues have developed an AI tool called iStar that can automatically spot tumors and types of cancer that are difficult for clinicians to see or identify and can predict candidates for immunotherapy. First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses Image: iStock/Love Employee First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses The therapy tested in a Phase 1 clinical trial might drastically change the way the T cells work, potentially allowing the new CAR T cell product to work where other products have failed.
First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses Image: iStock/Love Employee First in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses The therapy tested in a Phase 1 clinical trial might drastically change the way the T cells work, potentially allowing the new CAR T cell product to work where other products have failed.